US68404V1008 - Common Stock
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
OPTN stock results show that OptiNose met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OptiNose (NASDAQ:OPTN) just reported results for the fourth quarter of 2023.Opt...
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients...
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized...
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in...
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in...
Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in...
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE...
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and...